and Human Services (HHS)
EXPIRED
CLINICAL STUDY OF VESICOURETERAL REFLUX IN CHILDREN
RELEASE DATE: July 8, 2004
RFA Number: RFA-DK-04-019
September 16, 2009 - This RFA has been reissued as (RFA-DK-09-502).
(see amendment NOT-DK-04-010)
EXPIRATION DATE: March 17, 2005
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATION:
National Institutes of Health (NIH)
(http://www.nih.gov)
COMPONENT OF PARTICIPATING ORGANIZATION:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
(http://www.niddk.nih.gov/)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.849 NIDDK
Kidney Diseases, Urology and Hematology Research
LETTER OF INTENT RECEIPT DATE: February 16, 2005
APPLICATION RECEIPT DATE: March 16, 2005
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this RFA
o Research Objectives
o Mechanism(s) of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Supplementary Instructions
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS RFA
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
invites cooperative agreement applications for pediatric nephrology/urology
clinical treatment centers (CTC) and a data coordinating center (DCC)for the
design and conduct of treatment trials and studies in children with
vesicoureteral reflux (VUR). The primary goals of this study are to
determine: the relationship between renal scarring and decline in renal
function, the risk factors for decline in renal function, the impact of
prophylactic antibiotic use on preservation of renal function, and the role
for surgical intervention in the preservation of renal function and
prevention of recurrent urinary tract infections.
RESEARCH OBJECTIVES
Background
Vesicoureteral reflux (VUR), the retrograde flow of urine from the bladder to
the upper urinary tract, is one of the most common problems for which children
are referred to pediatric nephrologists and urologists. Clinical management
strategies range from observation, to prophylactic antibiotic administration
to various types of surgical intervention. There are no long-term, well
documented studies, which demonstrate the effectiveness of these various
clinical management strategies in preventing deterioration of renal function.
In addition, there are many other topics related to VUR for which there is
poorly documented data. For example, in the scientific literature there is a
lack of consistent correlation of VUR and renal scarring, as well as a lack of
correlation of antibiotic use, urinary tract infection and renal scarring.
Likewise, it is unclear whether surgical intervention improves outcome, and if
a delay abrogates potential benefit from intervention. On May 18, 2003, the
NIDDK sponsored a strategic planning workshop on the potential for conducting
a randomized controlled trial in children diagnosed with VUR. A summary of the
meeting and list of participants may be found at
http://www.niddk.nih.gov/fund/divisions/KUH/kuhconferences.htm. As indicated
above, the two big issues facing physicians who take care of this group of
patients are: a) when, and what type of surgical intervention is indicated,
and b) if and when antibiotic use is indicated. There are also difficulties in
choosing appropriate outcome measures of clinical significance. These
difficulties are compounded in children, since growth and development create
the need for long-term outcome measures.
Research Scope and Goals
The primary goals of this program are to study disease progression in a cohort
of 600 children with mild to moderate VUR (grade I III/IV) and to determine
which interventions are most beneficial. Examples that illustrate possible
areas of research are presented below. They are intended only to provide a
broad direction for research and should be considered illustrative and not
restrictive. Some potential areas of research are:
o The relationship between the extent of scarring and renal function
o An assessment of the effect of surgical intervention on preserving renal
function
o A comparison of the long-term outcomes of the different surgical approaches
o A comparison of the long-term efficacy of prophylactic antibiotic use in the
different grades of VUR
o Delineation of early biomarkers for change in renal function
o The impact of dysfunctional elimination syndrome (DES)
o Family history/heritability of VUR
Applicants should propose testable hypotheses on critical issues that can be
resolved in the context of this study.
MECHANISM OF SUPPORT
This RFA will use NIH U01 award mechanism. As an applicant you will be
solely responsible for planning, directing, and executing the proposed
project. This RFA is a one-time solicitation. Future unsolicited,
competing-continuation applications based on this project will compete with
all investigator-initiated applications and will be reviewed according to the
customary peer review procedures. The anticipated award date is September
2005. Applications that are not funded in the competition described in this
RFA may be resubmitted as NEW investigator-initiated applications using the
standard receipt dates for NEW applications described in the instructions to
the PHS 398 application.
This RFA uses just-in-time concepts. It also uses the modular budgeting as
well as the non-modular budgeting formats (see
http://grants.nih.gov/grants/funding/modular/modular.htm). Specifically, if
you are submitting an application with direct costs in each year of $250,000
or less, use the modular budget format. Otherwise follow the instructions
for non-modular budget research grant applications. This program does not
require cost sharing as defined in the current NIH Grants Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part2.htm.
The NIH U01 is a cooperative agreement award mechanism. In the cooperative
agreement mechanism, the Principal Investigator retains the primary
responsibility and dominant role for planning, directing, and executing the
proposed project, with NIH staff being substantially involved as a partner
with the Principal Investigator, as described under the section "Cooperative
Agreement Terms and Conditions of Award.
FUNDS AVAILABLE
The NIDDK intends to commit approximately $3 million in FY 2005 to fund five
Clinical Treatment Center (CTC) grants and one Data Coordinating Center grant
in response to this RFA. An applicant should request a project period of up
to five years. It is anticipated that the award for the DCC will not exceed
$800,000 total costs, excluding subcontract facility and administrative (F&A)
costs (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-040.html) .
The amount awarded to each CTC will not exceed $440,000 total costs per year,
excluding subcontract facility and administrative (F&A) costs
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-040.html).
Because the nature and scope of the proposed research will vary from
application to application, it is anticipated that the size of each award
will also vary. Although the financial plans of the IC(s) provide support for
this program, awards pursuant to this RFA are contingent upon the
availability of funds and the receipt of a sufficient number of meritorious
applications.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges,
hospitals, and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic institutions/organizations
o Foreign institutions are not eligible to apply as the applicant
organization; however consortia agreements to foreign institutions are
permitted
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
Each CTC must have at least one Pediatric Nephrologist and at least one
Pediatric Urologist as investigators. The Principal Investigator or Co-
Principal Investigator for a CTC may be either of those specialists. The
Principal Investigator of a CTC should have demonstrated experience in
enrolling patients in long-term, multicenter clinical trials and should be
familiar with clinical trial design concepts. The Principal Investigator of
the Data Coordinating Center (DCC) should have demonstrated expertise in
multicenter clinical trial design and in biostatistics. It is anticipated
that the DCC will also include experts in project management, data
collection, quality control, and other areas related to the efficient and
effective implementation of multicenter clinical trials.
SPECIAL REQUIREMENTS
The ability to recruit and retain a sufficient number of participants
into this study is the most important requirement for a successful
Clinical Coordinating Center. As preliminary evidence of that ability, each
Clinical Treatment Center applicant must provide an accurate, verifiable,
historical record of the number of eligible VUR patients seen per year for
the past three years. This record should be categorized by age, gender, race
and the grade of VUR. It is expected that during the study each Clinical
Coordinating Center will recruit a total of 120 eligible participants over a
period of 24 months. The Clinical Coordinating Centers and the Data
Coordinating Center must also agree to participate in a collaborative and
interactive manner with the other funded centers to develop the study
protocols and carry out the study.
Cooperative Agreement Terms and Conditions of Award
A. Applicability. These special Terms of Award are in addition to and not in
lieu of otherwise applicable OMB administrative guidelines, HHS grant
administration regulations in 45 CFR part 74 and 92, and other HHS, PHS and
NIH grant administration policy statements.
The administrative and funding instrument used to pay research projects
involving clinical trials, prevention and control interventions, or
epidemiological surveys in excess of $500,000 direct cost per year (at a
single institution or in the aggregate for studies proposing multi-
institutional collaborative arrangements submitted as either subcontracts to
a single application or as separate applications) shall be a cooperative
agreement, an "assistance" mechanism (rather than an "acquisition" mechanism)
in which substantial NIDDK scientific and/or programmatic involvement with
the awardee is anticipated during performance of the activity.
Under the cooperative agreement, the NIDDK purpose is to support and/or
stimulate the recipient's activity by involvement in and otherwise working
jointly with the award recipient in a partner role, but it is not to assume
direction, prime responsibility, or a dominant role in the activity.
Consistent with the above concept, the dominant role and prime responsibility
for the activity reside with the awardee(s) for the project as a whole,
although specific tasks and activities in carrying out the studies will be
shared among the awardees and the NIDDK Project Scientist or designee.
Under the cooperative agreement, a relationship will exist between the
recipient of these awards and the NIDDK, in which the performers of the
activities are responsible for the requirements and conditions described
below, and agree to accept program technical assistance, advice, and/or other
coordination above and beyond normal program stewardship from a named NIDDK
Project Scientist in achieving the project objectives.
Failure of an awardee to meet the performance requirements, including these
special terms and conditions of award, or significant changes in the level of
performance, may result in a reduction of budget, withholding of support,
suspension and/or termination of the award.
B. Awardee Rights and Responsibilities.
The Awardee is responsible for:
1. Research design and protocol development, including definition of
objectives and approaches, planning, implementation, participant recruitment
and follow-up, data collection, quality control, interim data and safety
monitoring, final data analysis and interpretation, and publication of
results.
2. Establishing a Steering Committee to coordinate and manage the project.
Awardee(s) will name investigators to serve as members on a Steering
Committee and other subcommittees, as appropriate, meeting periodically.
Awardees will be required to accept and implement the common protocol(s) and
procedures approved by the Steering Committee.
3. Designating Protocol Chairs. The Principal Investigators (for studies
involving multiple coordinated awards) shall designate a single Protocol
Chairperson (if the Principal Investigator does not assume this role) for
each protocol within the described research plan. The Protocol Chairperson
shall function as the scientific coordinator for the protocol and shall
assume responsibility for obtaining approval to implement the protocol from
the Steering Committee and for developing and monitoring the protocol. Any
significant modifications to approved protocols must be submitted to the
Steering Committee by the Protocol Chairperson.
4. Implementing the core data collection method and strategy collectively
decided upon by the Steering Committee. For a study involving multiple
institutions, it is the responsibility of each awardee/site to ensure that
data will be submitted in a timely way to the central Data Coordinating
Center. Additionally, individual investigators/sites must demonstrate the
ability to implement the strategy specifically designed for their individual
study population.
5. Establishing mechanisms for quality control and monitoring. Awardees are
responsible for ensuring accurate and timely assessment of the progress of
each study, including development of procedures to ensure that data
collection and management are: (1) adequate for quality control and analysis;
(2) for clinical trials, as simple as appropriate in order to encourage
maximum participation of physicians and patients and to avoid unnecessary
expense; and (3) sufficiently staffed across the participating institutions.
For research involving multiple awards, strategies for the analyses of pooled
data will be developed by the Steering Committee.
6. Submitting interim progress reports, when requested, to the NIDDK Program
Director including as a minimum, summary data on protocol performance. For
coordinated multiple awards or a multi-site single award, the Steering
Committee may require additional information from individual awardees/sites.
Such reports are in addition to the annual awardee noncompeting continuation
progress report.
7. Establishing procedures, where applicable, for all participating
institutions in coordinated awards to comply with FDA regulations for studies
involving investigational agents or devices and to comply with the
requirements of 45 CFR Part 46 for the protection of human subjects, and the
NIH policy requirements for the inclusion of women, minorities and children.
8. Cooperating in the reporting of the study findings. The awardee(s) will
retain custody of and have primary rights to the data developed under these
awards, subject to the Government rights of access consistent with current
HHS, PHS and NIH policies. The NIDDK will have access to and may
periodically review all data generated under an award. Where warranted by
appropriate participation, plans for joint publication with NIDDK of pooled
data and conclusions, are to be developed by the Principal Investigator or
Steering Committee, as applicable. NIH policies governing possible co-
authorship of publications with NIDDK staff will apply in all cases. In
general, to warrant co-authorship, NIDDK staff must have contributed to the
following areas: (a) design of the concepts or experiments being tested; (b)
performance of significant portions of the activity; and (c) preparation and
authorship of pertinent manuscripts.
9. Support or other involvement of industry or any other third party in the
study -- e.g., participation by the third party; involvement of study
resources or citing the name of the study or NIDDK support; or special access
to study results, data, findings, or resources -- may be advantageous and
appropriate. However, except for licensing of patents or copyrights, support
or involvement of any third party will occur only following notification of
and concurrence by NIDDK.
10. Study investigators are encouraged to publish and to release publicly
and disseminate results and other products of the study, in accordance with
study protocols and governances.
11. The NIDDK has established Central Biosample, Genetic, and Data
Repositories for the archival and storage of data and biosamples collected in
large, multi-site studies funded by NIDDK. The Data Coordinating Center
(DCC) will work with the NIDDK Biosample Repository to coordinate procedures
for coding, shipping, processing, receipt, and storage of study samples that
are to be maintained in the Repository. In addition, the DCC will coordinate
with the NIDDK Data Repository to prepare the collected data for eventual
archiving and distribution. All samples and data transferred to the
Repositories will be under the custodianship of the NIDDK, although the
study’s Steering Committee will have proprietary control of and exclusive
access to the samples and data for an agreed-upon period of time.
Subsequently samples and data will be available to the wider scientific
community in accordance with the NIH policy on Data Sharing
(http://grants.nih.gov/grants/policy/data_sharing/ and,
http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm#goals, and
http://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm)
through a process that will include prioritized distribution based on review
of the scientific merit of the proposed use. Therefore, it is expected that
samples and data collected will be available to the broader scientific
community, after a proprietary period, at no charge other than the cost of
reproduction and distribution.
C. NIDDK Staff Responsibilities
An NIDDK Project Scientist will have substantial involvement in the project
above and beyond normal stewardship and monitoring of the award, as described
below.
1. Being the contact point for all facets of the scientific interaction with
the awardee (s). As required for the coordination of activities and to
expedite progress, NIDDK may designate additional NIDDK staff to provide
advice to the awardee on specific scientific and/or analytic issues. Such
staff may include another Project Scientist or Analyst, who will provide
direct technical assistance to the awardees to optimize the conduct and/or
analysis of the study; or who may assist in the coordination of activities
across multiple sites.
2. For multi-institutional protocols, convening the first meeting of and
subsequent participation in the Steering Committee that oversees study
conduct. The NIDDK Project Scientist or designee will be a full participant
and voting member of the Steering Committee and, if applicable,
subcommittees.
3. Serving as a resource with respect to other ongoing NIDDK activities that
may be relevant to the protocol to facilitate compatibility and avoid
unnecessary duplication of effort.
4. Substantial involvement assisting in the design and coordination of
research activities for awardees as elaborated below:
a. Assisting by providing advice in the management and technical performance
of the investigations, coordinating clearances for investigational agents
held by NIDDK. The NIDDK may reserve the right to cross file or independently
file an Investigational New Drug Application form with the FDA.
b. For multi-institutional protocols, through participation in the Steering
Committee and with the agreement of the Principal Investigator(s) of any
coordinating center and data management centers, the NDDK Project Scientist
or designee may coordinate activities among awardees by assisting in the
design, development, and coordination of a common research or clinical
protocol and statistical evaluations of data; in the preparation of
questionnaires and other data recording forms; and in the publication of
results.
c. Reviewing and approving advice regarding the establishment of mechanisms
for quality control and study monitoring.
An NIDDK Program Director identified in the Notice of Grant Award will be
responsible for the normal stewardship and monitoring of the award. The
Program Director may also serve as the Project Scientist.
The NIDDK Program Director responsibilities include:
1. Retaining overall programmatic responsibility for the award, and will
clearly specify to the awardee the name(s) and role (s) of any additional
individuals with substantial involvement in the project and the lines of
reporting authority.
2. Interacting with the principal investigator(s) on a regular basis to
monitor study progress. Monitoring may include: regular communications with
the principal investigator and staff, periodic site visits for discussions
with awardee research teams, observation of field data collection and
management techniques, quality control, fiscal review, and other relevant
matters; as well as attendance at Steering Committee, data safety and
monitoring board, and related meetings. The NIDDK retains, as an option,
periodic external review of progress.
3. Reviewing and approving protocols to insure they are within the scope of
peer review and for safety considerations, as required by Federal
regulations. The NIDDK Program Director will monitor protocol progress, and
may request that a protocol study be closed to accrual for reasons including:
(a) accrual rate insufficient to complete study in a timely fashion; (b)
accrual goals met early; (c) poor protocol performance; (d) patient safety
and regulatory concerns; (e) study results that are already conclusive; and
(f) emergence of new information that diminishes the scientific importance of
the study question. The NIDDK will not permit further expenditures of NIDDK
funds for a study after requesting closure (except for patients already on-
study).
4. Making recommendations for continued funding based on: a) overall study
progress, including sufficient patient and/or data accrual; b) cooperation in
carrying out the research (e.g., attendance at Steering Committee meetings,
implementation of group decisions, compliance with the terms of award and
reporting requirements); and/or c) maintenance of a high quality of research,
which will allow pooling of data and comparisons across multiple cooperative
agreement awards for common data elements.
D. Joint Responsibilities
In addition to the interactions defined above, NIDDK Staff and Awardees shall
share responsibility for the following activities:
1. Steering Committee.
A Steering Committee organized by the Principal Investigator (or P.I. of the
Coordinating Center in the case of multiple coordinated awards) will be the
main oversight body of the study.
The Steering Committee has primary responsibility to design research
activities, establish priorities, develop common protocols and manuals,
questionnaires and other data recording forms, establish and maintain quality
control among awardees, review progress, monitor patient accrual, coordinate
and standardize data management, and cooperate on the publication of
results. Major scientific decisions regarding the core data will be
determined by the Steering Committee. The Steering Committee will document
progress in written reports to the NIDDK Program Director, and will provide
periodic supplementary reports upon request.
The Steering Committee will be composed of all Principal Investigator(s),
(including those of data coordinating /statistical centers, if any) and co-
investigators as deemed necessary, and the NIDDK Project Scientist or
designee. An initial meeting of the Steering Committee will be convened early
after award by the NIDDK Project Scientist or designee. The final structure
of the Steering Committee will be established at the first meeting. The NIDDK
Project Scientist or designee will have voting membership on the Steering
Committee, and as appropriate, its subcommittees. Such a committee usually
will meet at least twice yearly.
A Chairperson, other than the NIDDK representative, will be selected by a
vote of the members. The Chairperson is responsible for coordinating the
Committee activities, for preparing meeting agendas, and for scheduling and
chairing meetings.
2. Data Safety and Monitoring Board.
An independent Data and Safety Monitoring Board will be established by the
NIDDK for Phase III clinical trials. The Data and Safety Monitoring Board
will review interim results periodically and report to the Steering Committee
and NIDDK. In all other studies where warranted, the NIDDK Program Director
will facilitate and the awardee shall allow for interim data and safety
monitoring through the establishment of an independent (external) Data and
Safety Monitoring Board.
E. Arbitration
Any disagreement that may arise on scientific/programmatic matters (within
the scope of the award), between award recipients and the NIDDK may be
brought to arbitration. An arbitration panel will be composed of three
members --one selected by the awardee (or the Steering Committee, with the
NIDDK member not voting), a second member selected by NIDDK, and the third
member elected by the two prior selected members. These special arbitration
procedures in no way affect the awardee's right to appeal an adverse action
that is otherwise appealable in accordance with PHS regulations at 42 CFR
Part 50, Subpart D, and HHS regulations at 45 CFR Part 16.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research, peer review, and financial or grants management
issues:
o Direct your questions about scientific/research issues to:
Marva M. Moxey-Mims, M.D.
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Room 639
Bethesda, Maryland 20892-5458
Telephone: (301) 594-7717
FAX: (301) 480-3510
Email: [email protected]
Leroy M. Nyberg, M.D., Ph.D.
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Room 627
Bethesda, MD 20892-5458
Telephone: (301) 594-7717
FAX: (301) 480-3510
E-mail: [email protected]
Stuart Howards, M.D.
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Room 627
Bethesda, MD 20892-5458
Telephone: (301) 594-7717
FAX: (301) 480-3510
E-mail: [email protected]
o Direct your questions about peer review issues to:
Francisco O. Calvo, Ph.D.
Chief, Review Branch
National Institute of Diabetes, Digestive, and Kidney Diseases
6707 Democracy Boulevard, Room 752
Bethesda, Maryland 20892-5452
Telephone: (301) 594-8897
Fax: (301) 480-3505
Email: [email protected]
o Direct your questions about financial or grants management matters to:
Carolyn Kofa
Grants Management Specialist
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Room 727
Bethesda, Maryland 20892-5452
Telephone: (301) 594-7687
FAX: (301) 480-3504
Email: [email protected]
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes
the following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this RFA
Although a letter of intent is not required, is not binding, and does not
enter into the review of a subsequent application, the information that it
contains allows IC staff to estimate the potential review workload and plan
the review.
The letter of intent is to be sent by the date listed at the beginning of
this document. The letter of intent should be sent to:
Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 752
Bethesda, MD 20892-5452
(for express/courier service: Bethesda, MD 20817)
Telephone: (301) 594-8897
FAX: (301) 480-3505
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). Applications must have a DUN and
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the
Universal Identifier when applying for Federal grants or cooperative
agreements. The DUNS number can be obtained by calling (866) 705-5711 or
through the web site at http://www.dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of the PHS 398 form. The PHS
398 document is available at
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: [email protected].
SUPPLEMENTARY INSTRUCTIONS:
BUDGET: Clinical Centers should prepare a budget for each year of the program
not to exceed $440,000 total costs (direct and facilities and administrative
costs) per year. The funds for the DCC should not exceed $800,000 total costs
per year. The first 8 months of year 1 will be a period of intensive protocol
development with meetings of the steering committee to be held every other
month, generally in the Washington DC area. The total percent effort of the
Principal Investigator and co-investigator during this time should be
reflected on the budget page. It is anticipated that recruitment for the
clinical trial will begin in year 2. Applicants should budget for key
personnel for study coordination and data entry. Beginning in year 2 and for
the duration of the program applicants should budget for travel to three
meetings of the Steering Committee each year. These will generally be held
in the Washington DC, area. The DCC should budget for all key personnel,
describe % effort and description of responsibilities.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001)
application form must be affixed to the bottom of the face page of the
application. Type the RFA number on the label. Failure to use this label
could result in delayed processing of the application such that it may not
reach the review committee in time for review. In addition, the RFA title
and number must be typed on line 2 of the face page of the application form
and the YES box must be marked. The RFA label is also available at:
http://grants.nih.gov/grants/funding/phs398/labels.pdf.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the Checklist, and three signed, photocopies, in
one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application and all
copies of the appendix material must be sent to:
Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 752
Bethesda, MD 20892-5452
(for express/courier service: Bethesda, MD 20817)
APPLICATION PROCESSING: Applications must be received on or before the
application receipt date listed in the heading of this RFA. If an
application is received after that date, it will be returned to the applicant
without review.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.
However, when a previously unfunded application, originally submitted as an
investigator-initiated application, is to be submitted in response to an RFA,
it is to be prepared as a NEW application. That is, the application for the
RFA must not include an Introduction describing the changes and improvements
made, and the text must not be marked to indicate the changes from the
previous unfunded version of the application.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by the NIDDK. Incomplete and/or nonresponsive applications
will not be reviewed.
Applications that are complete and responsive to the RFA will be evaluated
for scientific and technical merit by an appropriate peer review group
convened by the NIDDK in accordance with the review criteria stated below.
As part of the initial merit review, all applications will:
o Undergo a process in which only those applications deemed to have the
highest scientific merit, generally the top half of the applications under
review, will be discussed and assigned a priority score
o Receive a written critique
o Receive a second level review by the National Diabetes and Digestive and
Kidney Diseases Advisory Council.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to evaluate the application in
order to judge the likelihood that the proposed research will have a
substantial impact on the pursuit of these goals. The scientific review group
will address and consider each of the following criteria in assigning the
application’s overall score, weighting them as appropriate for each
application.
o Significance
o Approach
o Innovation
o Investigator
o Environment
The application does not need to be strong in all categories to be judged
likely to have major scientific impact and thus deserve a high priority
score. For example, an investigator may propose to carry out important work
that by its nature is not innovative but is essential to move a field
forward.
SIGNIFICANCE: Does this study address an important problem? If the aims of
the application are achieved, how will scientific knowledge be advanced? What
will be the effect of these studies on the concepts or methods that drive
this field?
APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
INNOVATION: Does the project employ novel concepts, approaches or methods?
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?
INVESTIGATOR: Is the investigator appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to the experience level
of the principal investigator and other researchers (if any)?
ENVIRONMENT: Does the scientific environment in which the work will be done
contribute to the probability of success? Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements? Is there evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following
items will be considered in the determination of scientific merit and the
priority score:
1) Qualifications of Principal Investigator for CTC: The applicant must have
demonstrated experience in enrolling patients in long-term clinical trials.
2) Qualifications for Clinical Investigators for each CTC: Each CTC must have
at least on Pediatric Nephrologist and one Pediatric Urologist as
investigators.
3) Recruitment and Retention Capabilities: The application should discuss the
number of participants the Clinical Center anticipates will be recruited for
clinical trials. The application should provide evidence that the
investigators are capable of enrolling 5-7 participants per month for two
years. Applicants should describe the target population from which they
expect to recruit the required number of subjects as study participants.
They must also discuss plans for recruitment of minorities. The applicant
should include a brief discussion of previous relevant research efforts. The
applicant should discuss in detail the recruitment strategies which will be
utilized to procure the expected number of study participants. Specific
plans and previous experience in retaining randomized study participants for
the duration of clinical trial should also be discussed. Each Clinical
Treatment Center applicant must provide an accurate, verifiable, historical
record of the number of eligible VUR patients seen per year for the past
three years. This record should be categorized by age, gender, race and the
grade of VUR.
4) Proposed Clinical Trial Concept: The general concept draft for a single
randomized controlled clinical trial to be considered by the Steering
Committee of the Cooperative Treatment Group should be included in the
application. The general concept draft should not exceed two pages, and it
must be consistent with the scientific focus of this RFA. Concept issues to
be considered are identification of the intervention(s) and rationale,
primary and secondary outcome measures, sample size estimates and proposed
subgroup analyses.
5) Evidence of Institutional Support: There should be evidence of strong
institutional support for the Clinical Treatment Center, including adequate
space in which to conduct clinical activities and office space for staff.
6) Collaborative relationship between Pediatric Nephrology and Pediatric
Urology. The applicant should describe any already existing collaborative
clinical relationships between pediatric nephrology and pediatric urology.
7) The Data Coordinating Center should provide evidence of experience in
developing and conducting other multicenter clinical trials. They should
also submit a Clinical Trial Concept, as describer in item 4 above. Also,
methods for data collection, quality assurance, forms generation, meeting
planning, etc., should be discussed and delineated in the proposal.
8) Organizational Structure of Centers: Each applicant should include an
organizational structure of their CTC or DCC, delineating lines of authority
and responsibility.
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation
in the proposed research will be assessed. (See criteria included in the
section on Federal Citations, below).
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of
plans to include subjects from both genders, all racial and ethnic groups
(and subgroups), and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will also be
evaluated. (See Inclusion Criteria in the sections on Federal Citations,
below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL REVIEW CONSIDERATIONS
SHARING RESEARCH DATA: Applicants must describe their willingness to submit
data generated through this project to relevant publicly available databases
(http://grants.nih.gov/grants/policy/data_sharing/). The reasonableness of the
data sharing plan or the rationale for not sharing research data will be
assessed in all proposals by the reviewers. However, reviewers will not factor
the proposed data sharing plan into the determination of scientific merit or
priority score.
BUDGET: The reasonableness of the proposed budget and the requested period of
support in relation to the proposed research.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: February 16, 2005
Application Receipt Date: March 16, 2005
Peer Review Date: June 2005
Council Review: September 2005
Earliest Anticipated Start Date: October 2005
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o Scientific merit (as determined by peer review)
o Availability of funds
o Programmatic priorities.
REQUIRED FEDERAL CITATIONS
ANIMAL WELFARE PROTECTION: Recipients of PHS support for activities
involving live, vertebrate animals must comply with PHS Policy on Humane Care
and Use of Laboratory Animals
(http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf), as
mandated by the Health Research Extension Act of 1985
(http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA
Animal Welfare Regulations
(http://www.nal.usda.gov/awic/legislat/usdaleg1.htm), as applicable.
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
DATA AND SAFETY MONITORING PLAN: Data and safety monitoring is required for
all types of clinical trials, including physiologic, toxicity, and dose-
finding studies (phase I); efficacy studies (phase II); efficacy,
effectiveness and comparative trials (phase III). The establishment of data
and safety monitoring boards (DSMBs) is required for multi-site clinical
trials involving interventions that entail potential risk to the
participants. (NIH Policy for Data and Safety Monitoring, NIH Guide for
Grants and Contracts, June 12, 1998:
http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
SHARING RESEARCH DATA: Investigators submitting an NIH application seeking
$500,000 or more in direct costs in any single year are expected to include a
plan for data sharing or state why this is not possible.
http://grants.nih.gov/grants/policy/data_sharing Investigators should seek
guidance from their institutions, on issues related to institutional
policies, local IRB rules, as well as local, state and Federal laws and
regulations, including the Privacy Rule. Reviewers will consider the data
sharing plan but will not factor the plan into the determination of the
scientific merit or the priority score.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject participants for
all investigators submitting NIH proposals for research involving human
subjects. You will find this policy announcement in the NIH Guide for Grants
and Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2) cited
publicly and officially by a Federal agency in support of an action that has
the force and effect of law (i.e., a regulation) may be accessed through FOIA.
It is important for applicants to understand the basic scope of this
amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this RFA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the Standards for Privacy of Individually Identifiable Health Information ,
the Privacy Rule, on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on Am I a covered
entity? Information on the impact of the HIPAA Privacy Rule on NIH
processes involving the review, funding, and progress monitoring of grants,
cooperative agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore, we
caution reviewers that their anonymity may be compromised when they directly
access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This RFA is
related to one or more of the priority areas. Potential applicants may obtain
a copy of "Healthy People 2010" at http://www.healthypeople.gov/.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||